UAE Pharmaceutical Market: size, generics, local manufacturing and outlook 2026–2032

The UAE pharmaceutical market is small in volume, high in value per capita and historically dominated by originator brands sold through a few large distributors. Published estimates for 2025 range from USD 4.5 bn to USD 5.8 bn; our central estimate is USD 4.8 bn, growing at about 7% to USD 7.8 bn by 2032. Demand is driven by insurance coverage, chronic disease and specialist care; supply is shaped by MOHAP registration and pricing, insurer formularies, hospital-group tenders and the Tatmeen track-and-trace mandate.

Policy is moving the market toward generics and local manufacturing: MOHAP pricing reviews, insurer generic-substitution rules and the federal drive to localise production (Julphar, Neopharma, Globalpharma, new free-zone plants). For hospital groups, the practical lever is class-level tendering and biosimilar adoption, where savings of 20–40% on a category are routine.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 4.5 bn–USD 5.8 bn; differences are mostly scope.

Included: prescription and OTC pharmaceuticals, biologics and vaccines sold through hospitals, pharmacies and government channels. Excluded: medical devices, nutrition. Regulation: MOHAP (registration, pricing, Tatmeen); DoH and DHA (facility formularies, insurer rules); Emirates Drug Establishment (new federal authority).

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• UAE imports about 80% of its pharmaceutical products; 2,500+ medicines produced locally (The National)
• Generic drug sales were AED 2.5 bn in 2020, 19% of the total pharma market; 6,000+ generics available at ~60% below branded prices (The National)
• Manufacturing units grew from 4 in 2010 to 23 in 2021 (14 medicines, 4 devices, 2 disinfectants); EDE now lists 37 licensed facilities (2026) (The National / Gulf News)
• Tatmeen is MoHAP's GS1-standard serialisation and track-and-trace platform (built with EVOTEQ) covering locally made and imported medicines from manufacturer to patient; manufacturers affix GS1 barcodes before shipping (MoHAP)
• Julphar exports over 80% of production to ~40 markets; founded 45+ years ago (Gulf News)
• Diabetes affects ~1.3 mn UAE adults (19.3%); over 200 registered pharma companies compete in the market (Ken Research)
• Eleven pharma multinationals operate in the UAE incl. J&J, AstraZeneca, Novartis, Roche, Pfizer, GSK, Sanofi (The National)

UAE

Distribution runs through a concentrated group of agents (Pharmalink, Julphar, Al Ittihad, Gulf Drug, Mediclinic/Aster captive supply); hospital groups and PureHealth’s Rafed tender centrally; insurer formularies (Daman/Thiqa, DHA basic plan) drive generic uptake. Tatmeen serialisation is mandatory for all packs — see our Tatmeen guide.

India link

India is among the largest sources of generics for the UAE; registration requires a local agent, GMP evidence and MOHAP dossier; pricing is referenced to a basket of countries. Indian biosimilars (trastuzumab, bevacizumab, insulin glargine, enoxaparin) are increasingly on GCC tenders. See pharma product launch in the UAE.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers: registration takes 12–24 months; the local agent decides your shelf presence; plan Tatmeen aggregation data from the start.
• Hospital leaders: class-level lots, biosimilars and IV→oral programmes are the three savings levers; the drug repository gives the class members.
• Distributors: hospital groups want data (catalogue, serialisation events, fill rates) as much as product.

1. IMARC Group, UAE Pharmaceutical Market Size, Share, Trends and Forecast 2026-2034 — imarcgroup.com
2. Ken Research, UAE Pharmaceutical Market report 2025-2030 — kenresearch.com
3. BlueWeave Consulting, UAE Pharmaceutical Market (report sample) — blueweaveconsulting.com
4. Gulf News, UAE ramps up local medicine manufacturing with launch of Emirates Drug Establishment — gulfnews.com
5. Gulf News, Julphar plans to invest Dh300 million over next five years: CEO — gulfnews.com
6. Khaleej Times, UAE pharma sector poised for strong growth as localisation, AI reshape industry dynamics — khaleejtimes.com
7. MoHAP, Tatmeen — mohap.gov.ae
8. The National, UAE pharma market to be valued at $4.7bn by 2025 as it boosts local manufacturing — thenationalnews.com
9. IMARC Group (2026-09) — USD 4.45 bn (2025) to USD 8.59 bn (2034), CAGR 7.01% (2026-2034); scope: 2026E USD 4.99 bn; drugs 71.6% vs biologics; Dubai 39.7% of market — source
10. BlueWeave Consulting (2025-04) — USD 5.38 bn (2024) to USD 8.93 bn (2031), CAGR 7.5% (2025-2031); scope: Report ID BWC25202 — source
11. Ken Research (2025-11) — USD 4.2 bn (2024) to — (2030), CAGR —; scope: Five-year historical basis; generics described as dominant; Dubai and Abu Dhabi dominant emirates — source
12. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
13. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.